Learn, Analyse & Invest
only with
only with
+91
Download Orca
Bacil Pharma Ltd.
Bacil Pharma
₹ 0.00
0.00 (0.00)%
NSE
BSE
Healthcare
Small-cap - With a market cap of ₹81.74 Cr.
| EX-Date | Purpose |
|---|---|
| 30 06 2021 | Audited Results & Quarterly Results |
| 14 08 2021 | Quarterly Results |
| 12 11 2021 | Quarterly Results |
| 14 02 2022 | Quarterly Results |
| 30 05 2022 | Audited Results |
| 12 08 2022 | Quarterly Results |
| 02 11 2022 | Quarterly Results |
| 11 02 2023 | Quarterly Results |
| 16 05 2023 | Audited Results |
| 14 08 2023 | Quarterly Results |
| 10 11 2023 | Quarterly Results |
| 13 02 2024 | Quarterly Results |
| 27 09 2024 | Increase in Authorised Capital |
| 15 10 2024 | Inter alia, to discuss, consider and approve agendas as follows: - 1. To discuss and take final decision on acquisition of equity shares of M/s CNX Corporation Limited (CCL), from the existing shareholders of CCL, on which the Board of Directors has given their initial approval in its meeting held on 27th September 2024, the board will decide the no. of shares to be acquire, price of acquisition, mode of payment consideration etc. and other terms and conditions for acquisition of Eq. Shares of CCL subject to the due diligence and valuation reports in its meeting. 2. To discuss and approve the proposal for offer, Issue, and allot Equity Shares of the company on a Preferential Basis to the shareholders of M/s CNX Corporation Limited (CCL) for consideration other than cash (share swap), which will be determined in accordance with Chapter V of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 (SEBI ICDR Regulations), for a consideration other than cash (share swap)(for discharge of entire purchase consideration) to the shareholders of M/s CNX Corporation Limited (CCL), on such terms and conditions which will be approved by board in this meeting, subject to the shareholders approval in ensuing general meeting of the company. 3. To discuss and approve the proposal for fund raising by offer, Issue, and allot Equity Shares |
| 23 10 2024 | Quarterly Results |
| 21 01 2025 | Quarterly Results |
| 26 05 2025 | Audited Results |
| 16 07 2025 | Inter alia, to consider and approve:- 1. To consider and discuss the appointment of a new Executive Director and Chief Financial Officer (CFO) of the Company; 2. To consider and discuss the resignation of the present Chief Financial Officer (CFO) of the Company. 3. Any other business with the permission of chair. |
| 12 08 2025 | Quarterly Results |
| 25 08 2025 | Inter alia, to consider and approve:- 1. Discussion on Appointment of M/s Sarang Shivajirao Chavan& Associate as a Statutory Auditor of the Company; 2. Discussion on Appointment of New Director. 3. Any other business with the permission of Chairperson. |
| 05 09 2025 | Inter alia, To discuss and approve the following matters: ? Discussion on Notice for 38th Annual General Meeting for the Company. ? Discussion on Director Report of the Company for the Financial Year 2024-2025. ? Discussion to Fix Date, Place and Timing of 38th Annual General Meeting of the Company ? Discussion on matter related to Loan to Equity shares of the Company. ? Any other business with the permission of Chairperson. |
| 13 11 2025 | Quarterly Results |
| 13 02 2026 | Quarterly Results |
News
No News data available
